Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding.
The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures, among others.
In conjunction with the financing, Melissa McCracken, Ph.D. of Nextech will join Be Bio’s Board of Directors.
Led by CEO Joanne Smith-Farrell, Be Biopharma is providing engineered B Cell Medicines (BCMs) to improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions.
The company intends to use the funds to generate clinical proof-of-concept for BE-101 in the ongoing BeCoMe-9 Phase 1/2 clinical trial for people with hemophilia B and to advance BE-102 for the treatment of hypophosphatasia to the clinic.
Both programs are built on Be Bio’s BCM product platform, creating durable, titratable, and redosable therapeutics that require no preconditioning and produce sustained and constant levels of therapeutic proteins.
FinSMEs
15/01/2025